# Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet

> **NCT00954304** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 30 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HM30181AK 1mg
- **DRUG:** HM30181AK 5mg
- **DRUG:** HM30181AK 15mg
- **DRUG:** HM30181AK 60mg
- **DRUG:** Loperamide 2mg

## Key facts

- **NCT ID:** NCT00954304
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2010-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00954304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00954304, "Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00954304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*